Naveen's and Raquel's paper on de novo purine metabolism as a vulnerability of p16low cancers is out!

/

Congratulations to co-first authors Drs. Naveen Kumar Tangudu and Raquel Buj for this very nice study on a metabolic vulnerability in p16low cancers. Using multiple CRISPR screens and omics-based approaches, they identified de novo purine synthesis to be upregulated in p16low cancer cells. They also found that targeting this axis using anti-folates decreased proliferation of these cells both in vitro and in vivo. You can read the full text here: https://aacrjournals.org/cancerrescommun/article/doi/10.1158/2767-9764.CRC-23-0450/743061/De-novo-purine-metabolism-is-a-metabolic

New preprint on alpha-ketoglutarate and histone acetylation- congrats Dr. Apoorva Uboveja and co-authors

/

We are excited to share our newest preprint from 1st author Dr. Apoorva Uboveja. In this project, she found something totally unexpected- aKG affects histone acetylation through carnitine synthesis. This axis promoted DNA repair by homologous recombination. These data provide new evidence for a metabolically-sensitive epigenetic axis that could be targeted for cancer therapy. They also show that methylation is not the only epigenetic change that is affected by aKG. https://www.biorxiv.org/content/10.1101/2024.02.06.578742v1

New preprint alert! First authors Naveen and Raquel identify anti-folates as a strategy to treat cancers with p16 loss

/

Congrats to co-first authors Drs. Naveen Kumar Tangudu and Raquel Buj on their new preprint. Using CRISPR screens and pharmacological approaches, they identified purine metabolism as a metabolic vulnerability of p16-low cancers. Read more here: https://www.biorxiv.org/content/10.1101/2023.07.15.549149v2